NCT01366131
Completed
Phase 2
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin , Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease
ConditionsNon-Squamous Non-Small Cell Lung Cancer
Overview
- Phase
- Phase 2
- Intervention
- MEGF0444A
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Sponsor
- Genentech, Inc.
- Enrollment
- 104
- Primary Endpoint
- Progression-free survival (defined as the time from randomization to the first occurrence of progression based on RECIST 1.1 criteria or death from any cause on study)
- Status
- Completed
- Last Updated
- 9 years ago
Overview
Brief Summary
This is a Phase II, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of MEGF0444A combined with paclitaxel + carboplatin + bevacizumab therapy in patients with histologically or cytologically documented inoperable, locally advanced, metastatic (Stage IV), or recurrent non-squamous NSCLC.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologically or cytologically documented inoperable (Stage IV) or recurrent non-squamous non-small cell lung cancer (NSCLC). Diagnoses of non-squamous NSCLC that are based on sputum cytology alone are not acceptable. Mixed tumors should be categorized according to the predominant cell type.
- •ECOG performance status of 0 or 1
- •Life expectancy \>12 weeks
- •Measurable disease, as defined by RECIST 1.1
- •Adequate hematologic and end organ function
Exclusion Criteria
- •Prior therapy (including chemotherapy, antibody therapy, tyrosine kinase inhibitors,radiotherapy, immunotherapy, hormonal therapy or investigational therapy) before Day 1 of Cycle 1 for the treatment of Stage IV or recurrent NSCLC. Patients who received prior adjuvant chemotherapy or radiotherapy for NSCLC are not excluded if the time interval from completion of adjuvant therapy until disease progression is \> 12 months.
- •Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to enrollment
- •Malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, ductal carcinoma in situ treated surgically with curative intent
- •Pregnant and lactating women
- •Active infection requiring IV antibiotics
- •Bevacizumab-Specific Exclusions:
- •Histologically or cytologically documented inoperable, locally advanced, mixed non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component
- •Evidence of tumor invading major blood vessels on imaging
- •Evidence of central nervous system (CNS) metastases
- •History of stroke or transient ischemic attacks (TIAs) within 6 months prior to Day 1
Arms & Interventions
A
Intervention: MEGF0444A
A
Intervention: bevacizumab
A
Intervention: carboplatin
A
Intervention: paclitaxel
B
Intervention: bevacizumab
B
Intervention: carboplatin
B
Intervention: paclitaxel
B
Intervention: placebo
Outcomes
Primary Outcomes
Progression-free survival (defined as the time from randomization to the first occurrence of progression based on RECIST 1.1 criteria or death from any cause on study)
Time Frame: Up to 24 months
Secondary Outcomes
- Duration of objective response (defined as the first occurrence of a documented objective response until the time of progression or death from any cause on study)(Up to 24 months)
- Objective response (partial response plus complete response) as determined by the Investigator using RECIST 1.1(Up to 24 months)
- Overall survival (defined as the time from randomization until death from any cause)(Up to 24 months)
Similar Trials
Completed
Phase 2
Trial of VLTS-934 in Subjects With Intermittent Claudication Secondary to Peripheral Arterial DiseasePeripheral Vascular DiseaseNCT00113009Valentis148
Completed
Phase 2
A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal CancerMetastatic Colorectal CancerNCT01399684Genentech, Inc.127
Completed
Phase 2
A Phase 2 Study of Efficacy and Safety of AK111 in Subjects With Moderate-to-Severe PsoriasisPsoriasisNCT05096364Akeso251
Completed
Phase 2
A Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT02590965Hutchison Medipharma Limited91
Completed
Phase 2
Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast CancerBreast CancerNCT01186991Genentech, Inc.185